Tsinghua University

Protgen Ltd.

Beijing Protgen Ltd.

Medgenn (hong Kong) Ltd

Protogen Ltd.

Yantai Protgen Biotechnology Development Co., Ltd.

Yongzhang Luo

Yan Fu

Guodong Chang

Xiaofeng Wang

Peng Liu

Lei Gao

Xiaomin Song

Yang Chen

Xinan Lu

Yan Sun

Fei Wu

Hao Zhou

Wei Zhuo

Huadong Tang

Lin Jia

Daifu Zhou

Zhuobing Zhang

Qingxin Lei

Jinwan Wang

Hubing Shi

Qing Han

Dawei Cui

Chuntao Lu

Michuan Li

Shuling Yang

The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.

Nucleolin-mediated cancer diagnostics and therapy

Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.

Molecular design of recombinant protein drug

The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.

Endostatin mutants with mutations at ATP binding sites

The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.

Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy

The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90&#x3b1; having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.

Method of inhibiting or treating cancer metastasis

The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.

Methods and compositions for enhancing the uptake of therapeutic agents by target cells

The invention provides the uses of fibrinogen-420 or alpha EC domain thereof, for inhibiting protein aggregation, refolding the denatured proteins, manufacturing drugs for prevention and/or treatment of protein misfolding diseases, resisting protein denaturation, and detecting the quality of protein products. The invention also provides the drugs for prevention and/or treatment of protein misfolding diseases or protein denatured disease, and the protein stabilizer. The active ingredient of the said drugs and stabilizer is fibrinogen-420 or alpha EC domain thereof.

Application of fibrinogen-420 and its active domain

Method for cancer detection

The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence or metastasis of cancer by detecting plasma Hsp90&#x3b1; having the amino acid sequence of SEQ ID No. 1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.

Tumor biomarker

The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as a chemotherapy agent, or a radiotherapy agent.

Methods of treating cancer using a modified endostatin protein

Growing community of inventors

Beijing, China

Yongzhang Luo